New hope for tough cancers: first patients test novel drug

NCT ID NCT04900818

Recruiting now Disease control Sponsor: I-Mab Biopharma US Limited Source: ClinicalTrials.gov ↗

Summary

This is a first-in-human study to test the safety and find the right dose of a new drug called TJ033721 (givastomig) for people with advanced or metastatic solid tumors. It will enroll about 330 patients whose cancer has progressed despite standard treatments or who have no other good options. The study will also look at how the drug moves through the body and its early effects on certain cancers, including stomach, pancreatic, and bile duct cancers that have a specific marker called CLDN18.2.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Carolina BioOncology Institute
COMPLETED

Huntersville, North Carolina, 28078, United States
HARBIN Medical University Cancer Hospital
COMPLETED

Harbin, Heilongjiang, 150086, China
Henan Cancer Hospital
COMPLETED

Zhengzhou, Henan, 45003, China
Horizon Oncology Research, LLC.
COMPLETED

Layfayette, Indiana, 47905, United States
Hubei Cancer Hospital
COMPLETED

Wuhan, Hubei, 430079, China
Mary Crowley Cancer Research
COMPLETED

Dallas, Texas, 75230, United States
Mass General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NYU Langone
RECRUITING

New York, New York, 10016, United States
Rutgers Cancer Institute of New Jersey
COMPLETED

New Brunswick, New Jersey, 08901, United States
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
COMPLETED

Hangzhou, Zhejiang, 3110020, China
Sixth Affiliated Hospital, Sun Yat-sen University
ACTIVE_NOT_RECRUITING

Guangzhou, Guangdong, 510655, China
Stern Center for Cancer Clinical Trials and Research
RECRUITING

Orange, California, 92868, United States
The First Hospital of China Medical University
COMPLETED

Shenyang, Liaoning, 110499, China
The Second Hospital of Anhui Medical University
WITHDRAWN

Hefei, Anhui, 230601, China
Tianjin Medical University Cancer Institute and Hospital
COMPLETED

Tianjin, Tianjin Municipality, 300060, China
UCHealth Cancer Care - Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States
UW Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53705, United States
Vanderbilt-Ingram Cancer Center
COMPLETED

Nashville, Tennessee, 37232, United States
Zhongshan Hospital, Fudan University
COMPLETED

Shanghai, Shanghai Municipality, 200032, China

Conditions

Explore the condition pages connected to this study.

ADVANCED CANCER BILIARY TRACT CANCER (BTC) ESOPHAGEAL ADENOCARCINOMA GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CARCINOMA METASTATIC CANCER PDAC - PANCREATIC DUCTAL ADENOCARCINOMA SOLID TUMOR